Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar for first-line advanced hepatocellular carcinoma
ChiCTR2300078099Phase 2Recruiting
- Sponsor
- Shanghai Cancer Center
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab, oxaliplatin and raltitrexed in hepatocellular carcinoma (HCC), sponsored by Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Nov 2023; status: recruiting.
02
Drugs
sintilimabbevacizumaboxaliplatinraltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300078099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078099.